NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY

Show other versions (1)

Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires con...

Full description

Bibliographic Details
Main Authors: D. A. Napalkov, A. A. Sokolova
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-09-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
anticoagulants
atrial fibrillation
prevention of thromboembolism
warfarin
dabigatran
rivaroxaban
apixaban
Online Access:https://www.rpcardio.com/jour/article/view/193
id doaj-ef1ad42a0e174de288e3ca64e74cc1fa
record_format Article
spelling doaj-ef1ad42a0e174de288e3ca64e74cc1fa2021-09-03T13:15:13ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-09-0110444444710.20996/1819-6446-2014-10-4-444-447193NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETYD. A. Napalkov0A. A. Sokolova1I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityComparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding.https://www.rpcardio.com/jour/article/view/193anticoagulantsatrial fibrillationprevention of thromboembolismwarfarindabigatranrivaroxabanapixaban
collection DOAJ
language English
format Article
sources DOAJ
author D. A. Napalkov
A. A. Sokolova
spellingShingle D. A. Napalkov
A. A. Sokolova
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Racionalʹnaâ Farmakoterapiâ v Kardiologii
anticoagulants
atrial fibrillation
prevention of thromboembolism
warfarin
dabigatran
rivaroxaban
apixaban
author_facet D. A. Napalkov
A. A. Sokolova
author_sort D. A. Napalkov
title NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
title_short NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
title_full NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
title_fullStr NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
title_full_unstemmed NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
title_sort new oral anticoagulants: focus on the safety
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-09-01
description Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding.
topic anticoagulants
atrial fibrillation
prevention of thromboembolism
warfarin
dabigatran
rivaroxaban
apixaban
url https://www.rpcardio.com/jour/article/view/193
work_keys_str_mv AT danapalkov neworalanticoagulantsfocusonthesafety
AT aasokolova neworalanticoagulantsfocusonthesafety
_version_ 1717817123295723520

Similar Items